Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27117987 | 1.00 | KDM4E (0.45) | KDM4ECA1CA2CA4ALDH1A1 | |
| SCHEMBL16229734 | 1.00 | KDM4E (0.45) | KDM4ECA1CA2CA4ALDH1A1 | |
| SCHEMBL1437814 | 1.00 | KDM4E (0.45) | KDM4ECA1CA2CA4ALDH1A1 | |
| SCHEMBL25741004 | 1.00 | KDM4E (0.45) | KDM4ECA1CA2CA4ALDH1A1 | |
| SCHEMBL24930063 | 0.95 | — | — | |
| SCHEMBL10327054 | 0.95 | — | — | |
| SCHEMBL21227402 | 0.95 | — | — | |
| SCHEMBL21628350 | 0.82 | CA1 (0.34) | KDM4ECA1CA2CA4 | |
| SCHEMBL13745541 | 0.81 | CA1 (0.50) | KDM4ECA1CA2CA4ALDH1A1 | |
| SCHEMBL19055336 | 0.78 | ALDH1A1 (0.38) | KDM4ECA1CA2CA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024141535-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024044486-A1 | JAK2 INHIBITOR COMPOUNDS | AJAX THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023122581-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885CA1 4879/4885CA2 4600/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885CA1 4879/4885CA2 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.